Clinical Trials Browser

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07455032 2026-03-06

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Phase 1 Not yet recruiting

22 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Phase 1 Not yet recruiting

8 enrolled

CNS

Turcot syndrome, Glioblastoma

NCT04266730 2026-01-28

PANDA-VAC

Phase 1 Not yet recruiting

6 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT06724042 2025-12-10

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1 Not yet recruiting

159 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Phase 1 Not yet recruiting

30 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07199413 2025-09-30

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Phase 1 Not yet recruiting

20 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT07090369 2025-07-29

LumOnate

Phase 1 Not yet recruiting

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT06868732 2025-03-11

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Phase 1 Not yet recruiting

288 enrolled

Thoracic

Advanced Non-small Cell Lung Cancer

Clinical Trials

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

PANDA-VAC

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

LumOnate

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC